FMS - Fresenius Medical Care AG & Co. KGaA Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

FMS

FRESENIUS MEDICAL CARE AG & CO. KGAA

NYSE

$22.65

▲ UP 1.80% (0.40)

KEY STATISTICS

Market Cap$12.17 B

52w High$30.46

52w Low$20.02

Dividend Yield3.99%

FrequencyAnnual

P/E8.52

Volume567.51K

Shares Out.537.13M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Helen Giza

ABOUT

SECTOR

Healthcare

WENT PUBLIC

September 17, 1996

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

108,165

PRICE TARGET

Target High$25.80

Target Low$19.90

Target Median$24.50

Target Consensus$23.67

UPCOMING EARNINGS

DateNov 3, 2026

DayTuesday

Rev. Est.$5.65B

NOV

TUE

SPLIT RECORD

DATE	TYPE	RATIO
2012-12-04	Forward	2:1

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

6.46%

HOLDERS

371

TOP 8 OF 371 · RANKED BY POSITION SIZE

Pzena Investment Management LLC

15.1M sh

$339.59M

Fiduciary Management Inc /Wi/

Brandes Investment Partners, LP

1.9M sh

$43.32M

Millennium Management LLC

1.6M sh

$37.03M

Todd Asset Management LLC

1.3M sh

$29.51M

Point72 Asset Management, L.P.

1.1M sh

$26.98M

PRICE

$22.65 ▲ UP 1.80% (+$0.40)

OVERLAYS

About Fresenius Medical Care AG & Co. KGaA

https://www.freseniusmedicalcare.com ↗

Fresenius Medical Care provides global dialysis services, develops and distributes dialysis products, and offers related medical and pharmaceutical solutions through a network of clinics and hospital contracts.

INDUSTRY

Medical - Care Facilities

A PRODUCT FRESENIUS MEDICAL CARE AG & CO. KGAA IS KNOWN FOR

5008X CAREsystem

The 5008X CAREsystem is an FDA-cleared advanced hemodialysis machine enabling high-volume hemodiafiltration, offering a new standard of renal care in the U.S. with clinical evidence of reducing dialysis patient mortality.

COMPETITORS

COMPETITOR

Fresenius Medical Care AG & Co. KGaA in 2025

SENTIMENT: + POSITIVE

EARNINGS · NOVEMBER 2025

Fresenius Medical Care Raises Full-Year Guidance After Strong Q3 Performance and 28% Operating Income Growth

Fresenius Medical Care announced a significant 28% increase in operating income for the third quarter of 2025, leading the company to raise its full-year financial outlook. This strong performance was attributed to accelerating organic revenue growth and the successful execution of its 'FME Reignite' strategy, indicating a positive inflection in earnings and demonstrating the effectiveness of its ongoing transformation and portfolio optimization programs.

LEADERSHIP STRATEGY · JUNE 2025 · IN PROGRESS

Fresenius Medical Care Launches "FME Reignite" Strategy to Enhance Value Creation and Increase Profitability

In June 2025, Fresenius Medical Care unveiled its new comprehensive strategy, "FME Reignite," aimed at creating significant value through three core pillars: reigniting the core business, fostering growth and innovation, and revitalizing the company culture. This new strategic direction sets ambitious profitability targets for 2030 and introduces a new capital allocation framework to increase shareholder returns. [8, 11]